上海药明生物技术有限公司移出美国商务部“未核实清单”- 大数跨境

首页

上海药明生物技术有限公司移出美国商务部“未核实清单”

药明生物

2022-12-16

导读：药明生物一直遵守相关法律法规，并致力于以最严格的合规标准运营。

中国上海，

2022年12月16日

全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布子公司上海药明生物技术有限公司（WuXi Biologics (Shanghai) Co., Ltd.）今日正式从美国商务部的“未核实清单”（UVL）中移除。至此，药明生物两家子公司都已经移出UVL。

2022年2月，药明生物两家子公司——无锡药明生物技术股份有限公司（WuXi Biologics Co., Ltd.）和上海药明生物技术有限公司由于美国针对部分出口产品用途核实延期而被列入UVL。此后，两家子公司均在中国商务部的协调下成功完成了美国商务部的最终用户访问。10月7日，无锡药明生物技术股份有限公司正式从UVL中移除。

药明生物一直遵守相关法律法规，并致力于以最严格的合规标准运营。

关于药明生物

- 滑动查看更多药明生物介绍 -

药明生物（股票代码：2269.HK）是一家全球合同研究、开发和生产（CRDMO）服务公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。

药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过10000名员工。凭借这些员工组成的专业服务团队，以及卓越的技术和洞见，公司为客户提供高效经济的生物药解决方案。截至2022年6月底，药明生物帮助客户研发和生产的综合项目高达534个，其中包括14个商业化生产项目。

药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。如需更多信息，请浏览：www.wuxibiologics.com。

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI, China

Dec. 16, 2022

WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd. has been removed from the Unverified List (UVL) by the U.S. Department of Commerce, effective Dec. 16, 2022. Consequently, both subsidiaries WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co., Ltd. have been successfully removed from the UVL.

In February 2022, two subsidiaries of WuXi Biologics – WuXi Biologics Co., Ltd. and WuXi Biologics (Shanghai) Co., Ltd. – were placed on the UVL due to delayed verifications required for the receipt of certain products exported from the United States. Subsequently, both subsidiaries successfully completed the on-site end-use checks conducted by the U.S. Department of Commerce, in coordination with China's Ministry of Commerce (MOFCOM). WuXi Biologics Co., Ltd. was removed from the UVL on Oct. 7, 2022.

WuXi Biologics is committed to operating with the highest standard of compliance and in accordance with relevant laws and regulations.

About WuXi Biologics

- Scroll down from more introduction -

WuXi Biologics (stock code: 2269.HK) is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that empower partners to discover, develop, and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2022, WuXi Biologics is supporting 534 integrated client projects, including 14 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, further enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

注：本信息不构成药明生物的信息披露或投资建议

【声明】内容源于网络

药明生物

药明生物（2269.HK）是全球领先的生物制药技术平台公司

内容 0

粉丝 0

药明生物药明生物（2269.HK）是全球领先的生物制药技术平台公司

总阅读0

粉丝0

内容0